CD200在皮肤鳞癌进展过程中的表达

doi:10.3969/j.issn.1006-7795.2014.04.021

首都医科大学学报 ›› 2014, Vol. 35 ›› Issue (4): 488-491.doi: 10.3969/j.issn.1006-7795.2014.04.021

CD200在皮肤鳞癌进展过程中的表达

梅雪岭, 钟珊, 李妍, 王美芳

首都医科大学附属北京友谊医院皮肤科, 北京 100050

收稿日期:2014-06-25 出版日期:2014-08-21 发布日期:2014-07-22
通讯作者: 梅雪岭 E-mail:dayoff@vip.sina.com

CD200 expression in different stages of squamous cell carcinoma

Mei Xueling, Zhong Shan, Li Yan, Wang Meifang

Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2014-06-25 Online:2014-08-21 Published:2014-07-22

摘要/Abstract

摘要：

目的研究CD200蛋白在皮肤鳞癌不同进展阶段中的变化趋势。方法收集正常皮肤、日光性角化病、鲍温病、鳞癌、浸润鳞癌的皮肤组织标本各20例，免疫组织化学法检测CD200蛋白在组织中的表达。结果日光性角化、鲍温病、鳞癌和浸润鳞癌组织CD200的表达比例均较正常组织显著增高（P<0.01）；鳞癌和浸润鳞癌组织CD200的表达比例较日光性角化及鲍温病均显著增高（P<0.01）。结论 CD200的高表达可能促进了皮肤鳞癌的进展。

关键词: CD200, 皮肤, 鳞癌, 鲍温病, 日光性角化

Abstract:

Objective To study the trend of CD200 expression in different stages of squamous cell carcinoma. Methods To collect specimens of normal skin, actinic keratosis, Bowen's disease, squamous cell carcinoma and invasion squamous cell carcinoma and to detect the expression of CD200 by immunohistochemical method. Results Compared with normal skin, a significant increase is found in CD200 expression in actinic keratosis, Bowen's disease, squamous cell carcinoma and invasion squamous cell carcinoma(P<0.01). Compared with actinic keratosis and Bowen's disease, a significant increase is found in CD200 expression in squamous cell carcinoma and invasion squamous cell carcinoma(P<0.01). Conclusion High expression of CD200 may promote progression of squamous cell carcinoma.

Key words: CD200, skin, squamous cell carcinoma, Bowen’s disease, actinic keratosis

中图分类号:

R246.7

梅雪岭, 钟珊, 李妍, 王美芳. CD200在皮肤鳞癌进展过程中的表达[J]. 首都医科大学学报, 2014, 35(4): 488-491.

Mei Xueling, Zhong Shan, Li Yan, Wang Meifang. CD200 expression in different stages of squamous cell carcinoma[J]. Journal of Capital Medical University, 2014, 35(4): 488-491.

参考文献

[1] Lapouge G, Beck B, Nassar D, et al. Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness[J]. EMBO J, 2012,31(24):4563-4575.
[2] Rabinovich G A, Gabrilovich D, Sotomayor E M. Immunosuppressive strategies that are mediated by tumor cells[J]. Annu Rev Immunol, 2007,25:267-296.
[3] Talebian F, Bai X F. The role of tumor expression of CD200 in tumor formation, metastasis and susceptibility to T lymphocyte adoptive transfer therapy[J]. Oncoimmunology, 2012,1(6):971-973.
[4] Alapat D, Coviello Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma[J]. Am J Clin Pathol, 2012,137(1):93-100.
[5] Coles S J, Wang E C, Man S, et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia[J]. Leukemia, 2011,25(5):792-799.
[6] Holmannová D, Kolácková M, Kondelková K, et al. CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; Part II: CD200/CD200R potential clinical applications[J]. Acta Medica(Hradec Kralove), 2012,55(2):59-65.
[7] Memarian A, Nourizadeh M, Masoumi F, et al. Upregulation of CD200 is associated with Foxp3(+) regulatory T cell expansion and disease progression in acute myeloid leukemia[J]. Tumour Biol, 2013,34(1)531-542.
[8] Podnos A, Clark D A, Erin N, et al. Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6[J]. Breast Cancer Res Treat, 2012,136(1):117-127.
[9] Talebian F, Bai X F. The role of tumor expression of CD200 in tumor formation, metastasis and susceptibility to T lymphocyte adoptive transfer therapy[J]. Oncoimmunology, 2012,1(6):971-973.
[10] Olteanu H, Harrington A M, Kroft S H. CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma[J]. Am J Clin Pathol, 2012,138(6):867-876.
[11] Kawasaki B T, Mistree T, Hurt E M, et al. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells[J]. Biochem Biophys Res Commun, 2007,364(13):778-782.
[12] 刘梅,朱红,尹新江,等.皮肤基底细胞癌和鳞状细胞癌856例回顾性分析[J].中国医科大学学报,2013,44(12):1099-1101.
[13] Colmont C S, Benketah A, Reed S H, et al. CD200-expressing human basal cell carcinoma cells initiate tumor growth[J]. Proc Natl Acad Sci, 2013,110(4):1434-1439.

[1]	杜天舒, 宫晓丽, 艾孜儿·艾尼瓦尔, 张震, 刘玚, 王晓民, 张婷. CD200R1缺失促进脂多糖诱导的小胶质细胞内吞[J]. 首都医科大学学报, 2022, 43(1): 82-90.
[2]	林雪霏, 吴楠, 张海萍. 多汗症患者焦虑抑郁状态及睡眠情况研究[J]. 首都医科大学学报, 2021, 42(5): 841-846.
[3]	李沛霖, 崔磊. 真皮内脂肪组织调控皮肤生理病理过程与机制的研究进展[J]. 首都医科大学学报, 2020, 41(6): 896-900.
[4]	房达, 赵乾, 杜宁, 赵隶嬴, 马良, 崔石昌. 肝癌放射介入治疗患者辐射剂量的分析[J]. 首都医科大学学报, 2020, 41(3): 454-457.
[5]	冷菲, 李巍. 基于XGBoost对肺鳞癌和肺腺癌的分类预测[J]. 首都医科大学学报, 2019, 40(6): 889-893.
[6]	范晓娜, 姚健楠, 葛洋, 安广宇, 李鹰. DCLK1敲除对食管鳞癌细胞迁移和侵袭能力的影响[J]. 首都医科大学学报, 2019, 40(3): 417-423.
[7]	张俊俊, 王焱, 杜趁香, 晋熙梦. 脑特异性血管抑制因子-1在宫颈鳞癌中的表达及其与人乳头瘤病毒感染的关系[J]. 首都医科大学学报, 2018, 39(4): 569-574.
[8]	刘子莲, 张倩, 吴雯婷, 张春雷, 马川. 518例恶性皮肤肿瘤及癌前病变的回顾性分析[J]. 首都医科大学学报, 2018, 39(4): 602-606.
[9]	马思远, 娄鸿飞, 王成硕, 张罗. 北京地区可疑过敏性鼻炎病人吸入性变应原特征分析[J]. 首都医科大学学报, 2017, 38(5): 671-676.
[10]	程芮, 朱圣韬, 郭水龙, 李鹏, 郭庆东, 张澍田. 过表达DBHS家族基因可促进食管鳞癌细胞的迁移侵袭[J]. 首都医科大学学报, 2016, 37(1): 6-11.
[11]	邵琳琳, 赵佳佳, 朱圣韬, 郭水龙, 张澍田, 孙秀梅, 王拥军. DEC1参与顺铂诱导食管鳞癌的细胞衰老[J]. 首都医科大学学报, 2016, 37(1): 17-22.
[12]	段甦, 矫健, 张罗. 组胺对皮肤角化上皮屏障功能的作用的研究[J]. 首都医科大学学报, 2015, 36(4): 604-609.
[13]	王青釭, 孟莹, 朱圣韬, 施海韵, 张澍田. 启动子甲基化调节在低表达环氧合酶-2的食管鳞癌移植模型中的作用[J]. 首都医科大学学报, 2014, 35(6): 798-804.
[14]	孙秀静, 原标, 朱圣韬, 李鹏, 徐有青. 沉默PHF8重组慢病毒的制备及其对食管鳞癌细胞增生的影响[J]. 首都医科大学学报, 2014, 35(1): 122-128.
[15]	王向东;王成硕;宋晓红;伯铭羽;李颖;王鸿;张罗. 变应性真菌性鼻-鼻窦炎的综合诊断[J]. 首都医科大学学报, 2012, 33(6): 735-739.

CD200在皮肤鳞癌进展过程中的表达

CD200 expression in different stages of squamous cell carcinoma

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价